GW 766994

Drug Profile

GW 766994

Alternative Names: 766994; GW766994

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiallergics; Antiasthmatics; Small molecules; Urea compounds
  • Mechanism of Action CCR3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma

Most Recent Events

  • 01 Mar 2012 GlaxoSmithKline completes a phase II trial in Asthma in Canada (NCT01160224)
  • 14 Oct 2010 Phase-II clinical trials in Asthma in Canada (PO)
  • 30 Jan 2004 Phase-II clinical trials in Asthma (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top